Resilience

PartnerSlate is an online platform designed to facilitate strategic partnerships between food and beverage brands and manufacturing and packaging partners across North America. The platform enables brands to discover and connect with contract manufacturers by streamlining the manufacturing process through various criteria, such as location, capabilities, and product categories. This approach helps brands identify suitable production companies that align with their needs, ultimately supporting them in bringing their products to market efficiently. PartnerSlate serves as a valuable resource for the food industry, fostering relationships that enhance collaboration and drive business growth.

Swiftscale Biologics uses cell-free protein synthesis to enable the next generation of protein therapeutics.

Cellevolve Bio is a development and commercialization company focused on cell therapies.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.